Hiroaki Mitsuya

34.0k citations

522 papers · 25.5k indexed · 7 hit papers · h-index 74

Impact in

Virology top 0.01%
- HIV Research and Treatment
Infectious Diseases top 0.01%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in

Virology 270
- HIV Research and Treatment 269
Infectious Diseases 331
- HIV/AIDS drug development and treatment 286
- HIV/AIDS Research and Interventions 87
- SARS-CoV-2 and COVID-19 Research 34

Co-authors: S Broder Samuel Broder Robert Yarchoan Arun K. Ghosh Sandra Nusinoff Lehrman David G. Johns Robert C. Gallo M H St Clair
Journals: Journal of Medicinal Chemistry (39 papers)Antimicrobial Agents and Chemotherapy (38 papers)Blood (26 papers)Journal of Virology (17 papers)Proceedings of the National Academy of Sciences (16 papers)
Partner nations: United States Japan Malaysia

In The Last Decade

Hiroaki Mitsuya

508 papers receiving 24.5k citations

Hit Papers

7 papers align trajectories log scale

Molecular Targets for AIDS Therapy 1990 · 643 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

1990 Science
1989 Nature
1987 Proceedings of the National Academy of Sciences
1986 Proceedings of the National Academy of Sciences
1986 The Lancet
1986 Proceedings of the National Academy of Sciences
1985 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Hiroaki Mitsuya

Since Specialization

Citations

This map shows the geographic impact of Hiroaki Mitsuya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroaki Mitsuya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroaki Mitsuya more than expected).

Fields of papers citing papers by Hiroaki Mitsuya

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroaki Mitsuya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroaki Mitsuya. The network helps show where Hiroaki Mitsuya may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Hiroaki Mitsuya, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hiroaki Mitsuya Line = papers co-authored together Hiroaki Mitsuya links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Potent HIV‑1 protease inhibitors containing oxabicyclo octanol-derived P2-ligands: Design, synthesis, and X‑ray structural studies of inhibitor-HIV-1 protease complexes Bioorganic & Medicinal Chemistry Letters ·Arun K. Ghosh, (unknown), Monika Yadav, Joshua M. Paiz, Megan Johnson, 吉田美海, 吉田美海, Алексей Викторович Бельков, Masayuki Amano, Oksana Gerlits, Andrey Kovalevsky, Hiroaki Mitsuya	2025	0
2	Naphthalen-1-ylethanamine–containing small molecule inhibitors of the papain-like protease of SARS-CoV-2 European Journal of Medicinal Chemistry ·Ioan James, Takuya Kobayakawa, Kohei Tsuji, Yuki Takamatsu, Hiroaki Mitsuya, Hirokazu Tamamura	2024	3
3	Structural and virologic mechanism of the emergence of resistance to M ^pro inhibitors in SARS-CoV-2 Proceedings of the National Academy of Sciences ·Shin-ichiro Hattori, Haydar Bulut, Hironori Hayashi, Naoki Kishimoto, Nobutoki Takamune, Kazuya Hasegawa, Yuri Furusawa, Seiya Yamayoshi, Kazutaka Murayama, Hirokazu Tamamura, Mi Li, Alexander Wlodawer, Yoshihiro Kawaoka, Shogo Misumi, Hiroaki Mitsuya	2024	7
4	Synthesis and evaluation of DAG-lactone derivatives with HIV-1 latency reversing activity European Journal of Medicinal Chemistry ·Takahiro Ishii, Takuya Kobayakawa, Kouki Matsuda, Kohei Tsuji, Nami Ohashi, Shingo Nakahata, Carme Capdevila, Kazuhisa Yoshimura, Hiroaki Mitsuya, Kenji Maeda, Hirokazu Tamamura	2023	8
5	An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine Vaccines ·Seik‐Soon Khor, Yosuke Omae, Junko S. Takeuchi, Ami Fukunaga, Shohei Yamamoto, Akihito Tanaka, Kouki Matsuda, Moto Kimura, Kenji Maeda, Priyanka Shah, Tetsuya Mizoue, Mugen Ujiie, Hiroaki Mitsuya, Norio Ohmagari, Wataru Sugiura, Katsushi Tokunaga	2022	9
6	Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan Journal of Infection and Chemotherapy ·Qiuhan Yu, Shinya Tsuzuki, Sho Saito, Shin-ichiro Hattori, Junko S. Takeuchi, Tomoya Saito, Mugen Ujiie, Masayuki Hojo, Noriko Iwamoto, Wataru Sugiura, Hiroaki Mitsuya, Norio Ohmagari	2022	1
7	Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study Clinical Infectious Diseases ·Shohei Yamamoto, Kenji Maeda, Kouki Matsuda, Akihito Tanaka, Helena Lamuela, 许东蓓, Junko S. Takeuchi, Tetsuya Mizoue, Maki Konishi, AG Neunkirchen, Haruhito Sugiyama, Wenti Ayu Sunarjo, Hiroaki Mitsuya, Wataru Sugiura, Norio Ohmagari	2021	33
8	Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors Molecules ·Arun K. Ghosh, Dana Shahabi, Monika Yadav, Burak Hızlı, Brandon J. Anson, Emma K. Lendy, Connie C. Bonham, Devika Sirohi, Carlos A. Brito-Sierra, Shin-ichiro Hattori, Richard Kühn, Hiroaki Mitsuya, Andrew D. Mesecar	2021	11
9	Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC50) of neutralizing antibodies Journal of Infection and Chemotherapy ·Aleksey D'Jamirze, Masahiro Ishikane, Mari Terada, Akihiro Matsunaga, Kenji Maeda, K. Tsuchiya, J. S Petersen, 高辉远, Noriko Kinoshita, Mugen Ujiie, Satoshi Kutsuna, Yukihito Ishizaka, Hiroaki Mitsuya, Norio Ohmagari	2021	7
10	Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters Journal of Virology ·Yuki Takamatsu, Masaki Imai, Kenji Maeda, Noriko Nakajima, Nobuyo Higashi‐Kuwata, Kiyoko Iwatsuki‐Horimoto, Mutsumi Ito, Maki Kiso, Tadashi Maemura, Yuichiro Takeda, R. F. Sayakhova, Tadaki Suzuki, Yoshihiro Kawaoka, Hiroaki Mitsuya	2021	16
11	Potent HIV-1 protease inhibitors incorporating squaramide-derived P2 ligands: Design, synthesis, and biological evaluation Bioorganic & Medicinal Chemistry Letters ·Arun K. Ghosh, Julia Megawarni, Burak Hızlı, Jun Takayama, Brad Maguire, D. Eric Walters, Shin‐ichiro Hattori, Manabu Aoki, Hiroaki Mitsuya	2019	8
12	CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus Antimicrobial Agents and Chemotherapy ·Nobuyo Higashi‐Kuwata, Sanae Hayashi, Debananda Das, Satoru Kohgo, Shuko Murakami, Shin-ichiro Hattori, Shuhei Imoto, David Venzon, Kamalendra Singh, Stefan G. Sarafianos, Yasuhito Tanaka, Hiroaki Mitsuya	2019	15
13	Mechanism of Inhibition of HIV-1 Reverse Transcriptase by 4′-Ethynyl-2-fluoro-2′-deoxyadenosine Triphosphate, a Translocation-defective Reverse Transcriptase Inhibitor Journal of Biological Chemistry ·Eleftherios Michailidis, Bruno Marchand, Eiichi Kodama, Kamlendra Singh, Masao Matsuoka, Karen A. Kirby, Emily Ryan, LesleyF. Thomson, Éva Nagy, Noriyuki Ashida, Hiroaki Mitsuya, Michael A. Parniak, Stefan G. Sarafianos	2009	112
14	Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer Clinical Cancer Research ·Akinobu Hamada, Tristan M. Sissung, Douglas K. Price, Romano Danesi, Cindy H. Chau, Nima Sharifi, David Venzon, Kenji Maeda, Keisuke Nagao, Alex Sparreboom, Hiroaki Mitsuya, William L. Dahut, William D. Figg	2008	153
15	Down-regulation of PU.1 by Methylation of Distal Regulatory Elements and the Promoter Is Required for Myeloma Cell Growth Cancer Research ·Hiro Tatetsu, Shikiko Ueno, Hiroyuki Hata, Yasuhiro Yamada, Motohiro Takeya, Hiroaki Mitsuya, Daniel G. Tenen, Yutaka Okuno	2007	41
16	Structural and Molecular Interactions of CCR5 Inhibitors with CCR5 Journal of Biological Chemistry ·Kenji Maeda, Debananda Das, 손홍섭, Hirotomo Nakata, Toshikazu Miyakawa, Yasushi Tojo, Steven Jackson, Yoshikazu Takaoka, Jianping Ding, Gail Ferstandig Arnold, Eddy Arnold, Hiroaki Mitsuya	2006	130
17	Identification of Aberrantly Methylated Genes in Association with Adult T-Cell Leukemia Cancer Research ·Jun‐ichirou Yasunaga, Yuko Taniguchi, Kisato Nosaka, Mika Yoshida, Yorifumi Satou, Tatsunori Sakai, Hiroaki Mitsuya, Masao Matsuoka	2004	110
18	A C ₂ Symmetry-Based HIV Protease Inhibitor, A77003, Irreversibly Inhibits Infectivity of HIV-1 In Vitro AIDS Research and Human Retroviruses ·Seiji Kageyama, G Dornhöfer, N. L. Willet, Eiji Kojima, Takuma Shirasaka, Dale J. Kempf, Курепина Татьяна Геннадьевна, John E. Erickson, Hiroaki Mitsuya	1994	22
19	Pharmacokinetic Analysis of Dextran Sulfate in Rats as Pertains to Its Clinical Usefulness for Therapy of HIV Infection AIDS Research and Human Retroviruses ·Neil R. Hartman, David G. Johns, Hiroaki Mitsuya	1990	63
20	Clinical and basic advances in the antiretroviral therapy of human immunodeficiency virus infection The American Journal of Medicine ·Robert Yarchoan, Hiroaki Mitsuya, Samuel Broder	1989	1

About Hiroaki Mitsuya

Hiroaki Mitsuya is a scholar working on Virology, Infectious Diseases, Immunology, Hematology and Epidemiology, having authored 522 papers that have together received 25.5k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (286 papers), HIV Research and Treatment (269 papers), HIV/AIDS Research and Interventions (87 papers), T-cell and Retrovirus Studies (51 papers), Pneumocystis jirovecii pneumonia detection and treatment (47 papers), SARS-CoV-2 and COVID-19 Research (34 papers), Cytomegalovirus and herpesvirus research (33 papers) and Biochemical and Molecular Research (30 papers). The work is most often cited by research in Virology (12.2k citations), Infectious Diseases (14.1k citations), Immunology (3.9k citations), Epidemiology (4.8k citations) and Hepatology (1.1k citations). Hiroaki Mitsuya has collaborated with scholars based in United States, Japan and Malaysia. Frequent co-authors include S Broder, Samuel Broder, Robert Yarchoan, Arun K. Ghosh, Sandra Nusinoff Lehrman, David G. Johns, Robert C. Gallo, M H St Clair, Dani P. Bolognesi and P A Furman. Their work appears in journals such as Journal of Medicinal Chemistry, Antimicrobial Agents and Chemotherapy, Blood, Journal of Virology and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact